title: Regional myocardial perfusion assessed with generator-produced copper-62-PTSM and PET.
abstract: We have previously demonstrated that myocardial perfusion can be estimated accurately in experimental animals with the generator-produced positron-emitting tracer, 62Cu-pyruvaldehyde bis (N4-methylthio- semicarbazone)(62Cu-PTSM) and PET. This study evaluated the feasibility of quantifying regional myocardial blood flow using 62Cu-PTSM and PET in human subjects.
  
  
  METHODS
  Regional perfusion was estimated using a previously described and validated two-compartment model from dynamic PET scans obtained after an intravenous bolus of 62Cu-PTSM in 10 healthy volunteers and in 6 patients with coronary artery disease at rest: and in 9 of the volunteers and 4 of the patients after administration of dipyridamole intravenously. Flow estimates were compared with those obtained using H2(15)O.
  
  
  RESULTS
  Contrast was high between myocardium and blood or lung with 62Cu-PTSM, resulting in high-quality myocardial images. Liver uptake was also high. At flows of up to 1.5 ml/g/min, flow estimated with 62Cu-PTSM correlated closely with estimates obtained with H2(15)O (y = 0.71x .21, n = 169 regional comparisons, r = 0.66, p < 0.55), but this relationship was not maintained at higher flows.
  
  
  CONCLUSIONS
  The results demonstrate that quantification of myocardial perfusion with 62Cu-PTSM is feasible in human subjects but cannot be used to estimate hyperemic flows due most likely to the strong binding of the tracer to human serum albumin. Copper-62-PTSM congeners with less avidity for human albumin may prove more suitable for evaluation of hyperemic flows.
authors.affiliation: Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
authors.forename: P
authors.initials: P
authors.lastname: Herrero
authors.forename: J J
authors.initials: JJ
authors.lastname: Hartman
authors.forename: M A
authors.initials: MA
authors.lastname: Green
authors.forename: C J
authors.initials: CJ
authors.lastname: Anderson
authors.forename: M J
authors.initials: MJ
authors.lastname: Welch
authors.forename: J
authors.initials: J
authors.lastname: Markham
authors.forename: S R
authors.initials: SR
authors.lastname: Bergmann
mesh_terms: D000328:Adult; D003300:Copper / Q000493:pharmacokinetics; D003301:Copper Radioisotopes; D003326:Coronary Circulation / Q000502:physiology; D003327:Coronary Disease / Q000000981:diagnostic imaging*; D004176:Dipyridamole; D005240:Feasibility Studies; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000493:pharmacokinetics; D010104:Oxygen Radioisotopes; D011876:Radionuclide Generators; D012709:Serum Albumin / Q000378:metabolism; D013882:Thiosemicarbazones / Q000493:pharmacokinetics; D014055:Tomography, Emission-Computed; D014665:Vasodilator Agents
chemical_list: D003301:Copper Radioisotopes; D009942:Organometallic Compounds; D010104:Oxygen Radioisotopes; D012709:Serum Albumin; D013882:Thiosemicarbazones; D014665:Vasodilator Agents; C052629:copper pyruvaldehyde bis(N(4)-methylthiosemicarbazone) complex; D004176:Dipyridamole; D003300:Copper